G9091 Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t3, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
Short descriptor: Onc dx rectal t3 n0 no prog
Look up G9091 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
G9091 is the HCPCS Level II code for Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t3, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) (2026). It belongs to Section G — Procedures / Professional Services (Temporary). Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Not separately priced by Part B.
Classification & CMS Attributes
- Medicare Coverage
- Carrier judgment (code C)
- Part B Pricing
- Not separately priced by Part B (indicator 00)
- Type of Service
- Medical care
- Effective Date
- 2007-01-01
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference G9091 with the canonical source and edition:
G9091 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t3, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project). ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/G9091
Canonical URL: https://icd10codingpro.com/hcpcs-codes/G9091